5 funding opportunities found in this category. 

Request for Proposals: Hematology Oncology Pharmacy Association 2013 Research Award
Hematology Oncology Pharmacy Association
All Regions
06/14/2013
Inquire with funder

Request for Proposals: Hematology Oncology Pharmacy Association 2013 Research Award

The HOPA Foundation Board announces the opening of a call for proposals for the 2013 HOPA Foundation Research Award. The HOPA Foundation will fund up to 3 grants based on the stated scope of work. A total of $50,000 in funding is available to be awarded in 2013 through a competitive peer-review process described below.

Purpose

The individual award is intended to support a hematology/oncology pharmacy practice research project with subsequent publication that aligns with the strategic plan of the HOPA Foundation. Pharmacy practice is broadly defined including areas such as outcomes, surveys, patient safety, standards validation, and translational science applications. Multiple institutions may be involved in the project, and co-PI projects are allowed. The grant is open to all members of HOPA except standing members of the HOPA Foundation and HOPA Board Members.

Review

The HOPA research grants are intended to provide support for projects that are likely to result in facilitating the efforts of hematology/oncology pharmacists to optimize the care of individuals affected by cancer.

The HOPA Foundation Research Grant Review Panel will be chaired by a Foundation Board member; however its composition may vary based on the nature of the proposals received. Members will be comprised of individuals with expertise and familiarity in practice and research.

Application Process

1. A Letter of Intent (LOI) must be submitted electronically by June 14, 2013 to the attention of Susan Floutsakos at (sfloutsakos@connect2amc.com) who will act as the Grant Administrator.

2. The LOIs will be reviewed by members of the HOPA Foundation Research Grant Panel and a decision regarding acceptance for development into a full grant proposal in July 2013. Concepts presented in the LOI that do not address stated objectives and/or criteria of the RFP will be returned and not considered further with a letter of explanation.

3. Submitters of LOIs that are approved for development will be invited to prepare a full grant proposal using the current NIH format. Refer to http://grants.nih.gov/grants/funding/phs398/phs398.html for format. The grant proposals will be due by September 16, 2013. Grant applications must be submitted electronically as a single pdf file to Susan Floutsakos, (sfloutsakos@connect2amc.com) the Grant Administrator.

4. The public announcement of the awards will occur in late November 2013. All applicants will receive written feedback regarding review of their application.

Award Administration

1. Funds will be released to the investigator in their entirety, contingent upon Institutional Review Board approval, unless stipulations are placed on the disbursement by the HOPA Foundation Research Panel in its review of the application.

2. The awardee is required to submit a report of progress every six months to the HOPA Foundation Board Chair.

3. The awardee is expected to present the results of their research at the HOPA annual meeting. This presentation is expected to occur no later than two years after the release of the research funds. The results of the study are expected to be submitted for publication in a peer-reviewed biomedical print or online journal. The HOPA Foundation is to be acknowledged in any presentation or publication for its support of the research.

4. There is no provision for indirect costs in this research grant. A travel budget is expected to be included in the proposal to allow the presentation of the results at the HOPA annual meeting. Additional travel funds should be justified in the context of the needs of the project. Capital equipment purchases are not allowed in this grant.

5. All unused funds remaining from the grant 24 months after the disbursement must be returned to HOPA. The investigator may petition the HOPA Foundation for an extension for use of the funds. This request for an extension must be made at least six months before the expiration of the grant.

Clinical Pharmacist, Pharmacist
Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program
Cutaneous Lymphoma Foundation
All Regions
07/31/2013
$25,000

Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program

The signature funding initiative of the Research Awards Program (RAP), is the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions.  This research grant program supports investigators interested in conducting innovative cutaneous lymphoma research.   These grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies and, one day, a cure for cutaneous lymphoma are key goals of this program.

Research Funding Priorities

Eligibility and Requirements

Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive
awards. Medical students and graduate students are not eligible. Non-U.S. investigators are eligible and the research funded by the RAP can be conducted at non-U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.

Award Amounts

Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF
Board of Directors based upon the CLF Scientific Review Board’s review and recommendation.

A small indirect cost amount between $1,000-$2,000 is allowable.

The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:

-- Etiology and risk factors of cutaneous lymphomas.

-- Measures of disease impact on individuals and populations affected by cutaneous lymphomas.

-- Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.

-- Optimizing therapies for cutaneous lymphomas.

-- Improving quality of life for individuals with cutaneous lymphomas

2013 Calendar of Award Events

January 31 -  Public announcement of Request for Application (RFA)

July 31 -  Application deadline

August - October - Scientific Review Board review

November - Recipients notified of award

December - Grant awards announced at ASH meeting

January, 2014 - Disbursement of Award and beginning of new award cycle

Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374

Telephone: 248-644-9014

Fax: 248-644-9014

Junior Scientist, Young Scientist, Junior Faculty, Physician Researcher, Junior Researcher, Junior Investigator, Young Investigator, New Investigator, Established Investigator, Hematologist, New Researcher, Postdoctoral Fellow
2013 ASPIRE Hemophilia Research Awards
Pfizer
All Regions
05/20/2013
Inquire with funder

2013 ASPIRE Hemophilia Research Awards

As competition for research funding increases, the ASPIRE HEMOPHILIA program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research careers in Hemophilia A & B.

Mission

The mission of the ASPIRE Program is as follows.

• To support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis and treatment of hemophilia.

•To support academic research as well as the career development of promising young and established scientists.

Basic science and clinical research continue to advance our knowledge and understanding of Hemophilia A and Hemophilia B. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available.

The ASPIRE HEMOPHILIA program is designed to support basic science and clinical research in Hemophilia pathogenesis, host response and clinical outcomes in Hemophilia A and Hemophilia as well as translation of the resulting knowledge to bridge the gap between bench and bedside.

It is hoped that the results will lead to a better understanding of disease mechanisms and treatment options to enhance the clinical care of patients with Hemophilia A or Hemophilia B

Areas of Focus: Hemophilia A and Hemophilia B

Pfizer will support competitive grant programs which address one of the following areas in Hemophilia A and/or Hemophilia B.

Available Awards

Application is open to US investigators. Selection of research proposals will be performed by an independent, external expert panel comprised of nationally known academic clinicians. Project duration should be 1-2 years and should be approximately $125,000/year, inclusive of overhead costs.

To be eligible for an ASPIRE Hemophilia award, applicants must:

• have a doctoral degree (MD, PhD, PharmD, or equivalent);

• reside and practice in the United States.

Deadline for Application

• Applications must be received by Monday, May 20, 2013, 11:59 PM Eastern Daylight Time

• Addenda, supplemental materials, changes, or updates will not be accepted after the deadline

• Award decisions will be made in July 2013

• Successful applicants will be notified in July/August 2013

• The final study results or an interim progress report is expected on or before December 31, 2014

How to Apply

Applications should be submitted through the online submission website.

Questions

questions.aspireresearch-HEMOPHILIA@pfizer.com

Junior Scientist, Young Scientist, Physician Researcher, Junior Researcher, Junior Investigator, Young Investigator, New Investigator, Established Investigator, Hematologist, New Researcher
Leukemia & Lymphoma Society: The Quest For Cures
Leukemia & Lymphoma Society
All Regions
06/03/2013
Inquire with funder

Leukemia & Lymphoma Society: The Quest For Cures

The Leukemia & Lymphoma Society (LLS) is proud to announce The Quest For Cures (QFC), a new series of Request for Proposals (RFPs) to identify and develop safer, more effective treatment paradigms for patients with hematological malignancies. LLS has formed a partnership with Celgene to create the first of such RFPs that will build the foundation of this new LLS initiative. This initiative will identify and fund priority research areas, with support from biotech and pharmaceutical partners in order to address significant unmet medical needs. The near-term goal of this program is to advance the scientific and medical understanding of the various hematological malignances.

LLS is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services to patients and their families.

Celgene is a global biopharmaceutical company committed to improving the lives of patients' worldwide by delivering innovative and life-changing drugs for our patients. With more than 300 clinical trials, Celgene has focused on delivering novel therapies for patients with incurable hematological malignancies, including multiple myeloma, myeylodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), and myelofibrosis.

Description of The Awards:

The "Quest For CURES" research topics are aimed to gain a better understanding of the underlying causes leading to failure of current treatments and to identify novel therapeutic targets and ultimately new treatments. LLS and Celgene RFP topics available for funding with this initial RFP are the following:

Novel approaches for measuring and monitoring clonal heterogeneity in the clinical setting at both the genomic and epigenetic levels and assessing its contribution to response or resistance to therapy. Proposal topics of interest under this general area include but are not limited to the following:

a. Studies to define the proportions of genetically unique clones that have relevant mutations that can potentially drive resistance, either directly or by contributing to epigenetic plasticity.

b. Models in which to study the impact of targeting epigenetic modifying enzymes or other molecular targets on the development and evolution of clonal heterogeneity.

New molecular stratification mechanisms to identify key subsets of patients with B cell malignancies; application of these tools should be tractable to prospectively identify patients predicted to have poor outcomes with current standard therapies, aiming to direct these patients to novel therapeutic interventions that specifically address the identified cause(s) of treatment failure. Proposal topics of interest under this general area include but are not limited to the following:

a. Clinically tractable approaches to prospectively identify previously untreated DLBCL patients who are unlikely to achieve complete remission or who will have remission duration of less than a year following R-CHOP therapy. The approach should have potential for substantially greater sensitivity and specificity than the IPI or IHC based cell of origin methods and should additionally point to novel therapeutic targets.

Enhancing the understanding of the role of the microenvironment in initiation and maintenance of hematologic malignancies with emphasis on the mechanisms by which the elements of the microenvironment contribute to chemoresistance. Proposal topics of interest under this general area include but are not limited to the following:

a. Development of in vitro, 3-dimensional co-culture systems using primary and/or immortalized cell lines that recapitulate cell:cell interactions in the lymph node or bone marrow microenvironment. Proposals should describe how the superiority of these systems over currently available models would be demonstrated in terms of predicting sensitivity or resistance of leukemia or lymphoma cells to treatment.

b. Novel methods for utilizing clinical specimens to study the contributions of the lymph node and/or bone marrow microenvironments to response or resistance.

This RFP represents a new LLS research grant paradigm; QFC projects should, if successful, have a measurable impact on the diagnosis or treatment of patients with hematologic malignancies over the next 5 to 10 years. Proposals must include specific timelines, milestones and deliverables that researchers believe are achievable with their proposed funding. The range of funding available is from $200,000 to $400,000 annually, for research to be completed in a period of 2 years.

Additional funding, for projects that have demonstrated exceptional progress in the initial 2 years may be available; subject to review by LLS and its company partners. Additional funding is not guaranteed for any of the projects, but is contingent on the achievement of the project goals. The LLS Research Department staff will work with researchers to monitor progress and provide insight and expertise to each project. Both Celgene and LLS are committed to supporting early stage, foundational research as well as new therapy development. Researchers and institutions should note that Celgene would consider each project, as a project the company would potentially like to further develop as a potential therapeutic or diagnostic for patients.

Special Considerations for Grantees and Their Institutions:

In addition to LLS's standard terms and conditions for academic grant awards, QFC also includes the following requirements. In partnership with Celgene and their funding, academic institutions and researchers will have to agree to provide Celgene with first rights to negotiate for intellectual property deriving from or reduced to practice during each project. Should Celgene choose to negotiate for rights to IP, Celgene shall have an exclusive period for this negotiation. If an agreement is not reached the Institution and researcher may not enter into an agreement with terms any less favorable than what was last offered by Celgene for a certain period of time. Please inquire with LLS for disclosure of those time periods. Also, if after said period of time, the Institution has not entered into another agreement, Celgene shall have the right to elect to enter into another exclusive dealing period. During the period of the grant and the Periods when Celgene exercises its rights the institution is prevented from disclosing intellectual property rights outside normal activity or enter into negotiations with a third party. These specified periods for negotiation will be spelled out in the contract and available for review during the application process. Each applicant to the QFC is required to have his or her institution certify agreement with the IP terms and Celgene Rights at the time of application submission. For questions regarding this policy, please contact Allison Formal VP, Research Business Development at allison.formal@lls.org or at 914-282-2753.

WHO CAN APPLY

General Eligibility Criteria:

Citizenship and Degree - Applicants (principal investigator) must hold an M.D., Ph.D., or equivalent degree, and work in domestic or foreign non-profit organizations, such as universities, colleges, hospitals or other academic laboratories. Applications may involve multiple institutions however, the applicant (principal investigator) should have an independent research or academic position and his/her academic institution will be responsible for signing off on all terms of the QFC grant agreement. The applicant need not be a U.S. citizen, and there are no restrictions on applicant age, race, gender or creed. Applications from non-academic facilities and the National Institute of Health are not eligible. An applicant may only submit one application per RFP cycle in the QFC.

Leadership and Staffing - The application will require one principal investigator who is responsible for the preparation and submission of the proposal including budget, the conduct of the research programs and adherence with all stipulations made by LLS in this document, the Quest For Cures Guidelines and Instructions, the special terms outlined by LLS and Celgene, and in the grant contract if funded. Modifications to leadership and staffing are subject to the Relocation or Transfer and Interruption, Abandonment or Leave of Absence section of LLS's Policies & Procedures document.

APPLICATION PROCESS AND DEADLINES

The applicant and Sponsoring Institution must register independently with the proposal CENTRAL site in order for applicant to apply (see Instructions / General / Using proposal CENTRAL). Timelines and deadlines for the application process are shown below.

LETTERS OF INTENT (LOI) - Each applicant must submit an LOI by June 3, 2013 at 3:00 PM, ET via proposal CENTRAL website. LOIs will include a brief abstract describing the overall proposal, specific aims and projected milestones. LOIs will be reviewed for responsiveness to the RFP topics and approved/rejected by LLS shortly after the time of submission. Once the LOI has been approved, the Full Application will be available to the applicant on proposal CENTRAL for submission by July 15th, 2013.

FULL APPLICATION - Full applications will only be accepted via proposal CENTRAL. The submission deadlines will be strictly enforced. Please note that all times are Eastern Standard Time (EST). If any date falls on a weekend or a U.S. holiday, the deadline becomes the following business day.

There will be two review and funding cycles. The timeline for this initial cycle (Cycle 1) is detailed below. Applicants that do not receive funding during the first review cycle are ONLY eligible to re-apply with the same/similar proposal for the second review cycle by invitation. All applicants are welcome to submit entirely new proposals.

To apply please visit proposalCENTRAL by visiting the following url:  https://proposalcentral.altum.com/

Review Cycle 1

Call for Proposals February 2013

Letter of Intent Deadline June 3, 2013, 3:00, PM, ET

Full Application Deadline July 15, 2013, 3:00, PM ET

Scientific Peer Review Committee September 2013

Notification of Awards October 2013

Anticipated Funding Start Date December 2013

The topics for the second review cycle have not yet been determined. The application process for the second review cycle will begin in the summer 2013. There will be a separate announcement containing the topics and application deadlines for Cycle 2.

REVIEW PROCESS OF FULL APPLICATIONS

Full Applications will be reviewed after the July 15th submission deadline (Cycle 1) by a diverse peer review panel. Once ranked, the priority score and funding recommendations from the peer review panel will be presented to the Joint Steering Committee (LLS Research Staff and Celgene Representatives) for final determination of awardees.

Any applicant (PI) selected for funding will be notified within 45 days of the funding decision. Funding decisions are relayed by email only and are not available by telephone. All priority scores are confidential and are only available to LLS's Joint Steering Committee, LLS's Mission Oversight Committee, and administrative personnel only. Written critiques of the application are not formally provided to an applicant.

REVIEW CRITERIA

An application will be judged on the following criteria:

The probability of a significant advancement in the scientific and medical understanding of the hematological malignances

The conceptual basis upon which the proposal rests

A specific timeline with clearly articulated milestones and deliverables

The novelty of the concept

The feasibility of the research strategy

Thoughtful and clear presentation

The overall plan for bringing the research findings to clinical application

Experience, background, and qualifications of investigators

Adequacy of resources and environment (facilities, patient population, data management, and data analysis)

Adequacy of provisions for protection of human subjects if applicable

For additional questions regarding LLS research programs, eligibility and application processes, please contact Sammy Hattar, Director of Research Administration: Sammy.Hattar@lls.org or (914) 821-8290.

Physician Researcher, Hematologist
American Society of Hematology Physician-Scientist Career Development Award
American Society of Hematology
All Regions
09/01/2013
$42,000

American Society of Hematology Physician-Scientist Career Development Award

ASH developed the Physician-Scientist Career Development Award to immerse medical students between their first and second or second and third years of school in a one-year, full-time research experience in hematology.

Under the mentorship of outstanding faculty, medical student recipients of the ASH Physician-Scientist Career Development Award will experience in-depth exposure to hematology, thereby enhancing the likelihood that the funded students will ultimately pursue a career in hematology.

Award Amount
The award is for a one-year period, generally July 1 through June 30. Up to five awards will be awarded per year.

The total amount of the award is $42,000. The award is comprised of $28,000 to support the trainee, a $5,500 research allowance for supplies, $5,500 for insurance and educational expenses (including one course), and $3,000 for meeting attendance.

Awards will be paid directly to the participating institution of the mentor, not to the mentor or the recipient. Indirect costs (i.e., facilities and administration costs) are not allowed.

Timeline

September 1, 2013 Application Due

November 2013 Award Notification

July 1, 2014 Award Activation

Eligibility

Eligible applicants must:

•Submit a complete application.

•Be a first or second year medical student actively enrolled in a US or Canadian LCME or AOA COCA accredited medical school, and be in good standing relative to their course work, at the time of application.

•Be between their 1st and 2nd or 2nd and 3rd year of medical school at the time the research is done.

•Not be currently enrolled in a combined MD-PhD program. Students who earned a PhD prior to medical school will be considered on an individual basis if the field of PhD study lies outside of biomedical science.

•Be planning an investigative career in laboratory, translational, or clinical hematology research.

•Propose a project that may take place at the institution where the applicant is in medical school or at another institution with sufficient activity in hematology research and education as judged by the award study section.

•Propose a research project in hematology which will be exclusive to the applicant and will be conducted within the mentor’s lab.

•Have a research mentor who is an active ASH member at the time of application and remains a member for the duration of the award period. The mentor will oversee the progress and work of the award recipient, will assist in completing the program application, aid the recipient in their research, and ensure that the recipient meets all deadlines, including those for award reports. The mentor must have active research funding in hematology from NIH or an equivalent organization.

•Propose a research mentor who is a member of ASH in good standing at the time of Letter of Intent submission, and for the duration of the award period.

•Not have any other concurrent funding for a similar experience.

•Agree to spend more than 80% of his/her time conducting research during the one-year experience. Some clinical shadowing of hematologists or related providers during the year is allowed.

•Plan to conduct the research at an institution that will allow for continued enrollment in medical school and/or will provide an alternative mechanism for the student to maintain health, dental, and vision insurance during the award time period (up to $5,500 in funding is provided for premiums for this insurance).

No more than one award will be made to a student working with one mentor.

Additional Mentoring

ASH believes a multiple mentorship model is important for researchers regardless of their career stage. Therefore, the applicant may include a second mentor in his/her application to provide advice and support principally about career development but also for research questions. If the study section believes a second mentor is needed but the application does not include a second mentor, members of the study section will be responsible for identifying an appropriate mentor and facilitating contact.The additional mentor will coordinate with the research mentor to the extent that is feasible and desirable.

Application Process

•Applications MUST be submitted electronically to training@hematology.org by 11:59 pm, Eastern, September 1, 2013.

•Only electronic submissions will be accepted.

•The file should be named in the following format: Physician-Scientist Career Development Award Last name-First name Application 2014.pdf

•Only ONE submission will be accepted. No updates, revisions, changes, or additions will be accepted or considered.

•All submissions MUST include the required documents listed below, in the order below, and be submitted as one PDF file to be accepted or considered.

◦Complete Physician-Scientist Career Development Award Application Form

◦Project proposal (3 page limit, including figures, at 12 point font with .5 inch margins), and references (1 page limit at 12 point font with .5 inch margins)

◦Applicant career development plan (1 page limit at 12 point font with .5 inch margins)

◦Applicant Biosketch - Standard NIH format (4 page limit)

◦Mentor Letter of Support stating the support the applicant will receive from the mentor and the mentor’s institution (2 page limit at 12 point font with .5 inch margins).

◦Mentor Biosketch - Standard NIH format (4 page limit)

◦Institutional Letter of Support from a dean of the home institution of the applicant, or an appropriate leader of the institute where the research will be conducted, confirming that if accepted the applicant will continue to be enrolled in medical school and/or insurance will be maintained during the award period (1 page at 12 point font with .5 inch margins).

An email from ASH will be sent to the applicant within one business day of receiving the application to confirm receipt. If an email is not received, the applicant should notify ASH staff immediately. Failure to notify ASH could result in the application not being reviewed.

Any submission that does not follow the application requirements, is not formatted correctly, is lacking information, has incorrect information, or is lacking required documents will be deemed ineligible and will not be reviewed by the study section. There will be no appeals or consideration for additional or further review once an application has been determined to be ineligible.

ASH Annual Meeting Event

Award recipients must attend the ASH annual meeting and attend an orientation breakfast. During the breakfast, members of the Committee on Training Programs and the Trainee Council will be available to discuss specific areas of research as well as give award recipients advice on specific meetings, sessions, abstracts, or posters at the annual meeting which may be related to their area of interest.

Review Criteria

Criteria for review of the applications will include:

•The significance and originality of the proposed study and hypothesis.

•The appropriateness, feasibility, and adequacy of the proposed experiment and methodology.

•A focus on hematology basic, translational, or health sciences research.

•The qualifications and experiences of the applicant. Factors to be considered include, among others, the potential for future independent investigation and commitment to a career in hematology research.

•The qualifications of the mentor both in terms of past mentorship in hematology and also ability to lead the medical student to a successful end product of a submitted manuscript within the year of research work.

•The strength of the institutional letter of support as it pertains to the quality and level of support the applicant is to receive from the institution.

Award Terms

•The award is for a one-year period, July 1 through June 30 (off cycle exceptions can be allowed with explanation).

•For recipients with two year projects, an interim progress report is required at the half way point.

•Up to five awards will be awarded per year.

•The total award amount $42,000. The award is comprised of $28,000 to support the trainee, a $5,500 for research allowance for supplies, $5,500 for insurance and educational expenses (including one course), and $3,000 to for meeting attendance.

•Award recipients are required to attend the ASH annual meeting and attend the orientation breakfast. Funds to attend the ASH meeting will be paid from the funds allotted for meeting attendance.

•Payments are made to the institution at which the recipient will conduct his/her research in two equal installments first on July 1 and then on January 1.

•Depending upon curriculum requirements, it is the decision of each medical school as to whether or not the award recipient continues to be enrolled in medical school during the award period.

•Recipients must be conducting research at an institution that will allow for continued enrollment in medical school and/or alternative mechanism for the student to maintain health, dental, and vision insurance during the award time period (up to $5,500 in funding is provided for insurance premiums for and educational expenses).

•Recipients are to arrange for their own health insurance either through their institution or independently.

•Award recipients are expected to attend the ASH annual meeting and attend the orientation breakfast.

•At the conclusion of the award period, a final report is required highlighting the project’s progress and summarizing the usage of funds.

•All recipients must agree to provide a permanent email address.

•A record of award recipients will be kept and the contact information updated for at least 10 years after the award period.

•Following the award period, recipients are required to respond to all requests from the Society for information on their career progress as outlined in the Final Report and Monitoring section.

•Award funds cannot be deferred and are non-transferable.

•No-cost extensions may be requested by a recipient if needed. The letter will need to be submitted by the mentor in writing to the Committee on Training Programs Awards Subcommittee chair asking for a no-cost extension. It will be at the discretion of the Committee on Training Programs Awards Subcommittee and the study section chair to approve of the request. Any requests should be mailed to ASH with attention to the Training Department or emailed to training@hematology.org.

•For recipients granted a renewal, an interim progress report is required at the half way point.

•Receipt of the Physician-Scientist Career Development Award does not include or require an ASH Annual Meeting abstract submission.

•If selected for an award, the trainee will agree to cite support from the “American Society of Hematology (ASH)” in any publication or poster describing research conducted during the award period.

•Any visa and citizenship restrictions applicable to receiving Physician-Scientist Career Development Award are the responsibility of the applicant.

•All funds must be used to provide the award recipient a stipend and any supplies for the purposes of conducting the research submitted in the application. Indirect costs (i.e. facilities and administration costs) are not allowed for any Physician-Scientist Career Development Award. Violation will result in the revocation of the award funds.

•All ASH funding not spent by the end of the award term must be returned to the Society within ninety (90) days of submitting the final report. A check made out to the American Society of Hematology must be sent to the attention of the Training Manager at ASH Headquarters.

Additional Year Reapplication

Students making significant progress may submit a written request to renew the award for one additional year. Award renewal requests should be submitted at 9 months into the award period.These requests will be judged competitively against new award applications and on a case by case basis by considering the progress made during the first year of research.

Final Report Monitoring

ASH Physician-Scientist Career Development Award recipients are required to submit a final written report (not to exceed 4 pages).This will include a summary of research, manuscript submissions during the award period related to the funded research, presentations (locally and nationally) of the funded research during the award period, and educational goals met. This report must be sent to ASH Headquarters to the attention of the Training Manager. Members of the ASH Training Awards Subcommittee will evaluate final reports.

For recipients with two year projects an interim progress report is required at the half way point.

Failure to submit the final report, or an interim progress report, will render the applicant ineligible for future ASH funding.

Following the award period, recipients are required to respond to all requests from the Society for information on their career progress.

Questions?

If you have any questions or require any additional information regarding the Physician-Scientist Career Development Award, please contact training@hematology.org.

Medical Student